FDA Approval for Lurbinectedin
Lurbinectedin (brand name Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1]
Clinical Trial Evidence
Approval stemmed from the phase 2 basket trial (PM14-504), which showed an objective response rate of 35% in SCLC patients pretreated with platinum therapy. Median duration of response was 5.3 months, with median overall survival of 9.3 months.[2]
Off-Label and Investigational Uses
Lurbinectedin is studied in trials for other solid tumors, including:
- Platinum-resistant ovarian cancer (ORR 24% in combination with pegylated liposomal doxorubicin).
- Triple-negative breast cancer.
- Biliary tract cancers.
- Mesothelioma.
- Thymic carcinoma.
No approvals exist outside SCLC.[3]
How It Works in Cancer Cells
Lurbinectedin binds DNA minor grooves, trapping topoisomerase I and blocking transcription, leading to tumor cell death. It targets transcriptionally active cancers like SCLC, which has high neuroendocrine features.[4]
Comparison to Other SCLC Treatments
| Treatment | Approval Context | Median OS in Similar Trials |
|-----------|------------------|-----------------------------|
| Lurbinectedin | Post-platinum SCLC | 9.3 months |
| Topotecan | Post-platinum SCLC | 6.5 months |
| Irinotecan | Post-platinum SCLC | 7.8 months |
| Trilaciclib + chemo | Frontline SCLC | 10.6 months (additive) |
Lurbinectedin offers better tolerability than topotecan, with less myelosuppression.[5]
Ongoing Trials and Future Approvals
Over 50 active trials explore combinations (e.g., with atezolizumab, doxorubicin) in SCLC, NSCLC, and sarcomas. Phase 3 IMforte trial tests it with irinotecan in relapsed SCLC. No new indications approved as of 2024.[6]
Patient Access and Patent Status
Approved since June 2020. Orphan drug exclusivity for SCLC ends 2027; key patents expire 2030-2034. Check DrugPatentWatch.com for litigation updates.[7]
[1] FDA.gov - Zepzelca Approval (2020).
[2] J Clin Oncol. 2021;39(19):2143-2151.
[3] ClinicalTrials.gov - NCT02454972 et al.
[4] Nat Rev Clin Oncol. 2021;18:519-520.
[5] Lancet Oncol. 2020;21(11):1449-1461.
[6] ClinicalTrials.gov search: lurbinectedin.
[7] DrugPatentWatch.com - Zepzelca patents.